MDXG logo

MiMedx Group, Inc. Stock Price

NasdaqCM:MDXG Community·US$563.0m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 21 Fair Values set on narratives written by author

MDXG Share Price Performance

US$3.74
-2.75 (-42.37%)
US$6.50
Fair Value
US$3.74
-2.75 (-42.37%)
42.5% undervalued intrinsic discount
US$6.50
Fair Value
Price US$3.74
AnalystConsensusTarget US$6.50
AnalystHighTarget US$8.00
AnalystLowTarget US$6.00

MDXG Community Narratives

·
Fair Value US$6.5 42.5% undervalued intrinsic discount

Aging And Chronic Trends Will Redefine Surgical And Wound Care

0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
·
Fair Value US$8 53.3% undervalued intrinsic discount

Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$6 37.7% undervalued intrinsic discount

Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$8
53.3% undervalued intrinsic discount
Revenue
-3.67% p.a.
Profit Margin
7.4%
Future PE
58.43x
Price in 2029
US$9.85
US$6
37.7% undervalued intrinsic discount
Revenue
-0.094% p.a.
Profit Margin
6.45%
Future PE
41.51x
Price in 2029
US$7.39

Trending Discussion

Updated Narratives

MDXG logo

MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative

Fair Value: US$6.5 42.5% undervalued intrinsic discount
17 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MDXG logo

Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier

Fair Value: US$8 53.3% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MDXG logo

Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside

Fair Value: US$6 37.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

2 Risks
1 Reward

MiMedx Group, Inc. Key Details

US$389.4m

Revenue

US$73.8m

Cost of Revenue

US$315.6m

Gross Profit

US$284.9m

Other Expenses

US$30.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.21
81.04%
7.88%
7.2%
View Full Analysis

About MDXG

Founded
2006
Employees
808
CEO
Joseph Capper
WebsiteView website
www.mimedx.com

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Recent MDXG News & Updates

Narrative Update Jun 04

MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative

Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.
Seeking Alpha May 09

MiMedx: The Hard Math Behind My Downgrade To Hold

Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking Alpha

Recent updates

No updates